← Eichor
Study identifier: NCT04288427 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy

Condition: Benign Prostatic Hyperplasia · Prostate Hyperplasia · Prostate Disease  ·  Sponsor: Beth Israel Deaconess Medical Center

PhaseNA
Planned participants120
Who can joinMale, 50 Years to no upper limit
Healthy volunteersNo

About this study

The study is being conducted to learn why some patients with Benign Prostatic Hyperplasia (BPH) do not respond to a commonly used treatment drug, Finasteride. The hope is to find ways to predict which patients will not respond to Finasteride so that, in the future, these patients can be identified prior to offering this treatment and they can be offered alternative treatment strategies in its place. The aim is to see if noninvasive techniques such as MRI can detect inflammation of the prostate to assist with early detection of those who will and who will not respond to Finasteride.

This description comes directly from the study's public registry record.

Talk to the study team

Yulia Mulugeta, BS  ·  617-632-8890  ·  ymuluget@bidmc.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Beth Israel Deaconess Medical CenterBoston, Massachusetts, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04288427